Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
Sign Up to like & getrecommendations! Published in 2020 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13303
Abstract: This clinical trial (ChiCTR1800019185) is designed to be an open‐label, prospective, single‐center, single arm exploratory research study. The study will recruit non‐small cell lung cancer patients (NSCLC) with slow progression after first‐line treatment with EGFR‐TKI… read more here.
Keywords: treatment; study; tki treatment; progression ... See more keywords
The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
Sign Up to like & getrecommendations! Published in 2017 at "Integrative Cancer Therapies"
DOI: 10.1177/1534735416645181
Abstract: Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients… read more here.
Keywords: medicine; first line; treatment; tki treatment ... See more keywords
Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022018196
Abstract: Tyrosine kinase inhibitors (TKI) are very effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent leukemia stem cells persist as a barrier to cure. We performed a comprehensive evaluation of metabolic adaptation to TKI… read more here.
Keywords: stem; stem cells; cml stem; tki treatment ... See more keywords
Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1078118
Abstract: Background Immunological phenotypes and differentiation statuses commonly decide the T cell function and anti-tumor ability. However, little is known about these alterations in CML patients. Method Here, we investigated the immunologic phenotypes (CD38/CD69/HLA-DR/CD28/CD57/BTLA/TIGIT/PD-1) of T… read more here.
Keywords: cml; cell; cml patients; tki treatment ... See more keywords
Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.696881
Abstract: The histological transformation from epidermal growth factor receptor (EGFR)-mutated adenocarcinoma (ADC) to squamous cell carcinoma (SCC) after tyrosine kinase inhibitor (TKI) treatment is rare. We present a case of a patient who transitioned from early-stage… read more here.
Keywords: cell carcinoma; squamous cell; case; tki treatment ... See more keywords